Related references
Note: Only part of the references are listed.Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2019)
Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts
Ela Elyada et al.
CANCER DISCOVERY (2019)
Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model
Diane Bressand et al.
MOLECULAR PHARMACEUTICS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma
Kianna Y. Elahi-Gedwillo et al.
CANCER RESEARCH (2019)
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
Dnyaneshwar Kalyane et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2019)
IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma
Giulia Biffi et al.
CANCER DISCOVERY (2019)
Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer
Huan Meng et al.
ADVANCED DRUG DELIVERY REVIEWS (2018)
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Ana Costa et al.
CANCER CELL (2018)
Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment
Hiroyoshi Y. Tanaka et al.
CANCER SCIENCE (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer
Heather Nesbitt et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy
V. L. Veenstra et al.
ONCOGENESIS (2018)
Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma
Robert J. Torphy et al.
JCO PRECISION ONCOLOGY (2018)
Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer
Heidi Griesmann et al.
GUT (2017)
Immunotherapy in pancreatic cancer treatment: a new frontier
Komal Thind et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Daniel Ohlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
The role of stromal cancer-associated fibroblasts in pancreatic cancer
Dagny von Ahrens et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma
Kristina Y. Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer
Alvin P. Makohon-Moore et al.
NATURE GENETICS (2017)
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Matthias Pinter et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy
Kelsey J. Roberts et al.
CANCER CELL (2017)
Pancreatic cancer: Stroma and its current and emerging targeted therapies
Janaiah Kota et al.
CANCER LETTERS (2017)
An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer
Tianjiao Ji et al.
ACS APPLIED MATERIALS & INTERFACES (2016)
Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear Delivery of Gemcitabine and Doxorubicin to Pancreatic Cancer Cells
Tayebeh Anajafi et al.
BIOCONJUGATE CHEMISTRY (2016)
Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer
Bo Zhang et al.
BIOMATERIALS (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems
Merel van Elk et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer
Georg Dimcevski et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Pavan P. Adiseshaiah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
Andrew H. Ko et al.
PANCREAS (2016)
Pericyte-fibroblast transition promotes tumor growth and metastasis
Kayoko Hosaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials
Minnie Au et al.
BIOMEDICINES (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival (vol 25, pg 719, 2014)
Berna C. Oezdemir et al.
CANCER CELL (2015)
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer Normalization, Not Destruction
Clifford J. Whatcott et al.
CANCER JOURNAL (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma
Yanmiao Huo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Design considerations for nanotherapeutics in oncology
Triantafyllos Stylianopoulos et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer
Juan Vaz et al.
PANCREAS (2015)
Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Netai C. Singha et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways
Fabienne Guillaumond et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
Stimuli-responsive biodegradable poly(methacrylic acid) based nanocapsules for ultrasound traced and triggered drug delivery system
Peng Yang et al.
BIOMATERIALS (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer
Sheridan M. Hoy
DRUGS (2014)
Evaluation of the Steal Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer
Kate M. Bailey et al.
PLOS ONE (2014)
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
John J. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Pancreatic cancer and its stroma: A conspiracy theory
Zhihong Xu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer
Hideya Onishi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies
Agnieszka Anna Rucki et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
Erkut Borazanci et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2014)
Using Functional Nanomaterials to Target and Regulate the Tumor Microenvironment: Diagnostic and Therapeutic Applications
Tianjiao Ji et al.
ADVANCED MATERIALS (2013)
Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer
P. P. Provenzano et al.
BRITISH JOURNAL OF CANCER (2013)
Pirfenidone Inhibits Pancreatic Cancer Desmoplasia by Regulating Stellate Cells
Shingo Kozono et al.
CANCER RESEARCH (2013)
Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
Antonio Jimeno et al.
CLINICAL CANCER RESEARCH (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
Dereck Amakye et al.
NATURE MEDICINE (2013)
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
Albrecht Neesse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice
Atsushi Masamune et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Vikash P. Chauhan et al.
NATURE COMMUNICATIONS (2013)
Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
Vesselina G. Cooke et al.
CANCER CELL (2012)
Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment
Feng Yang et al.
CANCER TREATMENT REVIEWS (2012)
Ultrasound Microbubbles for Molecular Diagnosis, Therapy, and Theranostics
Fabian Kiessling et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
Mert Erkan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma
Jieqiong Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Stromal biology and therapy in pancreatic cancer
Albrecht Neesse et al.
GUT (2011)
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Hideaki Ijichi et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
H. Cabral et al.
NATURE NANOTECHNOLOGY (2011)
Cyclopamine and Hedgehog Signaling: Chemistry, Biology, Medical Perspectives
Philipp Heretsch et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice
Chiyo Doi et al.
BMC CANCER (2010)
Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Curtis B. Thompson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Selective Filtering of Particles by the Extracellular Matrix: An Electrostatic Bandpass
Oliver Lieleg et al.
BIOPHYSICAL JOURNAL (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Cancer-Stellate Cell Interactions Perpetuate the Hypoxia-Fibrosis Cycle in Pancreatic Ductal Adenocarcinoma
Mert M. Erkan et al.
NEOPLASIA (2009)
RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sindy Sohr et al.
CELL CYCLE (2008)
A paracrine requirement for hedgehog signalling in cancer
Robert L. Yauch et al.
NATURE (2008)
Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cells
Bryan P. Toole et al.
SEMINARS IN CANCER BIOLOGY (2008)
Nanocarriers as an emerging platform for cancer therapy
Dan Peer et al.
NATURE NANOTECHNOLOGY (2007)
Extracellular control of TGFβ signalling in vascular development and disease
Peter ten Dijke et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers
Georg Feldmann et al.
CANCER RESEARCH (2007)
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling
Mitsunobu R. Kano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Drug penetration in solid tumours
Andrew I. Minchinton et al.
NATURE REVIEWS CANCER (2006)
Angiotensin II promotes the proliferation of activated pancreatic stellate cells by Smad7 induction through a protein kinase C pathway
K Hama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Angiotensin II stimulates DNA synthesis of rat pancreatic stellate cells by activating ERK through EGF receptor transactivation
K Hama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
MJ Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
SR Bramhall et al.
BRITISH JOURNAL OF CANCER (2002)
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
SR Bramhall et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
